SGLT-2 inhibitors reduce adverse CV events associated with restenosis in stents in patients with type 2 diabetes.

Published Date: 13 Mar 2023

Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...

Read Full News

Latest News

New Model May Improve Surgical Risk Prediction in Cirrhosis

A new European risk model may improve the prediction of postoperative mortality in patients with cirrhosis.

GLP-1s Tied to Lower Risk of Psychiatric Decline

A Swedish national cohort study shows some GLP-1s — semaglutide in particular — are associated with reduced risk of psychiatric decline in patients with depression or anxiety.

A1c or CGM Metrics: Which Should Be the Gold Standard?

Two experts debated the question at the recent Advanced Technologies and Treatments for Diabetes meeting.

Frequent Insulin Infusion Site Failures ‘a Huge Problem’

Unexplained hyperglycemic events may be due to undetected occlusions, a common problem that experts say needs to be addressed through education and technology.

Four-Drug Regimen Superior to Escalating Metformin in T2D

Adding a fourth oral antidiabetic drug to a triple regimen beats metformin dose escalation for achieving glycemic control.

Keto Diet Boosts Aerobic Fitness in Hyperglycemic Mice

In hyperglycemic male mice, a ketogenic diet normalizes blood glucose and restores response to aerobic training.

Todays Updates

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.

Todays Updates

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.

Latest News

A new European risk model may improve the prediction of postoperative mortality in patients with cirrhosis.

A Swedish national cohort study shows some GLP-1s — semaglutide in particular — are associated with reduced risk of psychiatric decline in patients with depression or anxiety.

Two experts debated the question at the recent Advanced Technologies and Treatments for Diabetes meeting.

Unexplained hyperglycemic events may be due to undetected occlusions, a common problem that experts say needs to be addressed through education and technology.

Adding a fourth oral antidiabetic drug to a triple regimen beats metformin dose escalation for achieving glycemic control.

In hyperglycemic male mice, a ketogenic diet normalizes blood glucose and restores response to aerobic training.

News All Time

Tight Glycemic Target in Gestational Diabetes Reduces Risks

Tight glycemic targets in gestational diabetes can lower the risk for large-for-gestational-age births without increasing the risk for serious maternal and neonatal complications.

One-third Of Americans Cut Back on Other Expenses to Cover Healthcare in 2025, Survey Shows

Roughly one-third of Americans cut back on food, utilities or other daily expenses to pay for healthcare last year, research ⁠from the West Health-Gallup Center showed on...

Insulet Recalls Some Insulin Devices in US Over Leakage Risk

Insulet has recalled specific batches of its insulin-delivery pods in the ⁠U.S. after finding a manufacturing defect that could stop diabetic users from ⁠getting their full...

Social Risk Alerts Prompt Better Blood Pressure Control

The intervention also involves adding Z codes to patient records.

Psychosocial Risk: Loneliness as a Diabetes Predictor

Pooled results from nine cohorts of 1 million people show loneliness raises type 2 diabetes risk by 32%; asking ‘Do you feel lonely?’ could inform preventive care.

GLP-1 Persistence for Weight Loss Has Nearly Doubled

Patients without diabetes treated with GLP-1s for weight loss are remaining on the drugs without gaps, and switching drugs when needed may help sustain persistence.

Intraperitoneal Insulin an Option for Select T1D Patients

An upcoming international position statement will clarify the small number of patients for whom the MiniMed Implantable Infusion Pump might be considered appropriate.

Drugs Compared for Steroid-Linked Osteoporosis: What’s Best?

Patients with glucocorticoid-induced osteoporosis on romosozumab show greater gains in lumbar spine bone mineral density than those on denosumab and comparable gains with those on teriparatide.

Reclassification From Type 2 to Type 1 Diabetes Not Uncommon

Those who were misdiagnosed had higher healthcare utilization, suggesting potential benefits of broader autoantibody screening.

India Warns Drugmakers Against Weight-Loss Drug Ads

India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns that could...

Digital Microsteps Help GLP-1 Users Adopt Healthy Behaviors

Digitally delivered behavior-change prompts plus short videos can boost GLP-1 users’ expectations to adopt healthy lifestyle behaviors.

From Open Surgery to AI in Kidney Stone Care

Miniaturized percutaneous techniques, flexible ureteroscopy, and outpatient protocols have shortened hospital stays and improved recovery, reshaping quality-of-life outcomes for patients.

Early Introduction of Tirzepatide Yields T2D Benefits

Two-year data from Eli Lilly’s SURPASS-EARLY trial show reduced A1c, body weight, and cardiovascular risk factors.

West Virginia Can Ban Medicaid Coverage for Gender-affirming Surgery, US Court Rules

A U.S. appeals court on Tuesday upheld West Virginia's ban on Medicaid coverage for gender-affirming surgeries, the latest victory for Republican-led states seeking to curb...

Eli Lilly to Invest $3 Billion in China

Eli Lilly plans to invest $3 billion in China, which ⁠will help build production capacity for its experimental type-2 diabetes and obesity treatment orforglipron.

Majority of Papillary Thyroid Cancer Cases Are Overdiagnosis

Study finds up to 94% of papillary thyroid cancers in the past three decades were overdiagnosed, with stable mortality rates, despite soaring detection rates.

Recommended News For You

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

a brand-new generic therapy for different types of cancer.

Immunotherapy in Head and Neck Cancer After Failure of Definitive Therapy.

Severe obesity associated with reduced prevalence of recommended cancer screenings

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.

New study elucidates obesity's role in fueling breast cancer progression

Year in Review: Chronic Lymphocytic Leukemia

Recommended Articles For You

Exploring the Benefits of Endari: How This Natural Remedy Can Help You Live a Healthier Life 

Debunking Myths About Systemic Mastocytosis: Separating Fact from Fiction  

Unraveling the Mysteries of Coagulopathy: A Comprehensive Definition 

Benefits of Neutrophilia: Harnessing the Power of White Blood Cells to Promote Health and Well-Being 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise.

2.

Smart exercise planning could boost recovery for people with cancer

3.

Updates from the 2022 WHO classification of kidney epithelial tumors

4.

ALK-positive lung cancer trial results show unprecedented progression-free survival.

5.

After two years, a significant left nasal obstruction was finally diagnosed.

1.

Impact of Hormone Therapy Cessation on Tumor Growth: Case Study of Ki-67 Reduction

2.

Gut microbiota in curing cancer

3.

Revolutionizing Cancer Treatment with Mercaptopurine: A New Hope for Patients

4.

Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection

5.

Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

2.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

3.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

4.

Navigating the Complexities of Ph Negative ALL - Part I

5.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot